Expanding the universe of new treatments for patients

Arrakis Therapeutics to Participate in Upcoming Investor Conferences

Waltham, MA –  March 31, 2022 –  Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that company management will participate in the following upcoming investor conferences:

Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare
Michael Gilman, Ph.D., Chief Executive Officer of Arrakis, will participate in a panel discussion on Thursday, April 7, 2022 at 11:00 a.m. ET in New York. Company management will also participate in one-on-one meetings.

21^st Annual Needham Virtual Healthcare Conference
Company management will participate in one-on-one meetings on Tuesday, April 12, 2022.

About Arrakis Therapeutics
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts. For more information, please visit www.arrakistx.com and engage with us on Twitter @ArrakisTx or on LinkedIn.

Media Contact:
Kathryn Morris
914-204-6412
[email protected]

Investor Contact:
Will O’Connor
212-362-1200
[email protected]